



For immediate distribution  
Source: DIAGNOS Inc.

**2014.11.25**

## **DIAGNOS Opens Mexican Subsidiary Diagnos Internacional, S.A. de C.V.**

Brossard, Quebec, Canada – November 25, 2014 - DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces today the opening of its Mexican Subsidiary, Diagnos Internacional, S.A. de C.V..

According to the International Diabetes Federation, Mexico has the 6<sup>th</sup> largest diabetic population in the world. With a population of 8.7 million people suffering from diabetes, the region has become a target for Diagnos.

“Recognizing the elevated rate of diabetes and its complications in Latin America, we have been involved in field trials and business development efforts in the region for some time now, and are in a position to materially and constructively help local authorities with retinopathy screening projects. Following several successful pilot projects in the country, we now have dedicated a sales team and opened a local subsidiary in order to open the door to larger projects,” said André Larente, DIAGNOS’ President.

### About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including natural resources, healthcare, and entertainment.

### Forward-looking information

This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

André Larente, President and CEO  
Telephone: 1-877-678-8882 or (450) 678-8882, ext.: 224  
alarente@diagnos.ca